Cited 49 times in
Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박준용 | - |
dc.contributor.author | 안상훈 | - |
dc.date.accessioned | 2022-05-09T17:22:20Z | - |
dc.date.available | 2022-05-09T17:22:20Z | - |
dc.date.issued | 2022-04 | - |
dc.identifier.issn | 1542-3565 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/188530 | - |
dc.description.abstract | Background & aims: Predictors of successful nucleo(s)tide analogue (NA) therapy withdrawal remain elusive. We studied the relationship between end-of-treatment levels of hepatitis B core-related antigen (HBcrAg) and hepatitis B surface antigen (HBsAg) and outcome after therapy cessation. Methods: Patients who discontinued NA therapy in centers in Asia and Europe were enrolled. HBcrAg and HBsAg were measured at treatment cessation, and associations with off-treatment outcomes were explored. The SCALE-B (Surface antigen, Core-related antigen, Age, ALT, and tenofovir for HBV) score was calculated as previously reported. End points included sustained virologic response (VR; hepatitis B virus DNA level <2000 IU/mL), HBsAg loss, and alanine aminotransferase (ALT) flares (>3× upper limit of normal). Re-treated patients were considered nonresponders. Results: We analyzed 572 patients, 457 (80%) were Asian and 95 (17%) were hepatitis B e antigen positive at the start of NA therapy. The median treatment duration was 295 weeks. VR was observed in 267 (47%), HBsAg loss was observed in 24 (4.2%), and ALT flare was observed in 92 (16%). VR (67% vs 42%) and HBsAg loss (15% vs 1.5%) was observed more frequently in non-Asian patients when compared to Asian patients (P < .001). Lower HBcrAg levels were associated with higher rates of VR (odds ratio [OR], 0.701; P < .001) and HBsAg loss (OR, 0.476; P < .001), and lower rates of ALT flares (OR, 1.288; P = .005). Similar results were observed with HBsAg (VR: OR, 0.812; P = .011; HBsAg loss: OR, 0.380; P < .001; and ALT flare: OR, 1.833; P < .001). Lower SCALE-B scores were associated with higher rates of VR, HBsAg loss, and lower rates of ALT flares in both Asian and non-Asian patients (P < .001). Conclusions: In this multicenter study, off-treatment outcomes after NA cessation varied with ethnicity. Lower levels of HBcrAg and HBsAg were associated with favorable outcomes. A risk score comprising both factors can be used for risk stratification. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | W.B. Saunders | - |
dc.relation.isPartOf | CLINICAL GASTROENTEROLOGY AND HEPATOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Antiviral Agents / therapeutic use | - |
dc.subject.MESH | DNA, Viral | - |
dc.subject.MESH | Hepatitis B Core Antigens | - |
dc.subject.MESH | Hepatitis B Surface Antigens* | - |
dc.subject.MESH | Hepatitis B virus / genetics | - |
dc.subject.MESH | Hepatitis B, Chronic* | - |
dc.subject.MESH | Humans | - |
dc.title | Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE) | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Milan J Sonneveld | - |
dc.contributor.googleauthor | Jun Yong Park | - |
dc.contributor.googleauthor | Apichat Kaewdech | - |
dc.contributor.googleauthor | Wai-Kay Seto | - |
dc.contributor.googleauthor | Yasuhito Tanaka | - |
dc.contributor.googleauthor | Ivana Carey | - |
dc.contributor.googleauthor | Margarita Papatheodoridi | - |
dc.contributor.googleauthor | Florian van Bömmel | - |
dc.contributor.googleauthor | Thomas Berg | - |
dc.contributor.googleauthor | Fabien Zoulim | - |
dc.contributor.googleauthor | Sang Hoon Ahn | - |
dc.contributor.googleauthor | George N Dalekos | - |
dc.contributor.googleauthor | Nicole S Erler | - |
dc.contributor.googleauthor | Christoph Höner Zu Siederdissen | - |
dc.contributor.googleauthor | Heiner Wedemeyer | - |
dc.contributor.googleauthor | Markus Cornberg | - |
dc.contributor.googleauthor | Man-Fung Yuen | - |
dc.contributor.googleauthor | Kosh Agarwal | - |
dc.contributor.googleauthor | Andre Boonstra | - |
dc.contributor.googleauthor | Maria Buti | - |
dc.contributor.googleauthor | Teerha Piratvisuth | - |
dc.contributor.googleauthor | George Papatheodoridis | - |
dc.contributor.googleauthor | Benjamin Maasoumy | - |
dc.identifier.doi | 10.1016/j.cgh.2020.12.005 | - |
dc.contributor.localId | A01675 | - |
dc.contributor.localId | A02226 | - |
dc.relation.journalcode | J02981 | - |
dc.identifier.eissn | 1542-7714 | - |
dc.identifier.pmid | 33309804 | - |
dc.subject.keyword | HBcrAg | - |
dc.subject.keyword | HBsAg | - |
dc.subject.keyword | SCALE-B | - |
dc.subject.keyword | Sustained Response | - |
dc.contributor.alternativeName | Park, Jun Yong | - |
dc.contributor.affiliatedAuthor | 박준용 | - |
dc.contributor.affiliatedAuthor | 안상훈 | - |
dc.citation.volume | 20 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | e784 | - |
dc.citation.endPage | e793 | - |
dc.identifier.bibliographicCitation | CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, Vol.20(4) : e784-e793, 2022-04 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.